MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile

When do Mivacron In Dextrose 5% In Plastic Container patents expire, and what generic alternatives are available?

Mivacron In Dextrose 5% In Plastic Container is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER is mivacurium chloride. There are two drug master file entries for this compound. Additional details are available on the mivacurium chloride profile page.

Summary for MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	21
Clinical Trials:	5
DailyMed Link:	MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Université Libre de Bruxelles	N/A
University Hospital Ostrava	N/A
Jiangsu Nhwa Pharmaceutical Co., Ltd.	Phase 2

See all MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER clinical trials

US Patents and Regulatory Information for MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER	mivacurium chloride	INJECTABLE;INJECTION	020098-002	Jan 22, 1992		DISCN	No	No
Abbvie	MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER	mivacurium chloride	INJECTABLE;INJECTION	020098-003	Jan 22, 1992		DISCN	No	No

Expired US Patents for MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER	mivacurium chloride	INJECTABLE;INJECTION	020098-002	Jan 22, 1992	4,761,418

International Patents for MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

See the table below for patents covering MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	193996	PROCESS FOR PRODUCING NEW COMPOUNDS OF SCELETAL MUSCULES RELAXING ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AS ACTIVE AGENTS
Hungary	T40626
U.S.S.R.	1468414	CПOCOБ ПOЛУЧEHИЯ ПPOИЗBOДHЫX ИЗOXИHOЛИHИЯ (METHOD OF PRODUCING DERIVATIVES OF ISOQUINOLINE)
Israel	75833	ISOQUINOLINE DERIVATIVES,THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Ireland	58138	Bis-dimethoxymethyl(trimethoxybenzyl)isoquinolinium salts, their preparation and pharmaceutical compositions containing them

Supplementary Protection Certificates for MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0181055	SPC/GB93/031	United Kingdom		SPC/GB93/031:, EXPIRES: 20071207
0181055	96C0001	Belgium		PRODUCT NAME: MIVACURIUM CHLORID.= MIVACURIUM (+5% OVERDOSERING); NAT REG.: 251 IS 152 F 12 19951114; FIRST REG.: GB 0003/0325 19921208

Market Dynamics and Financial Trajectory for MIVACRON in Dextrose 5% in Plastic Container

Last updated: March 27, 2026

What is the current market landscape for MIVACRON in Dextrose 5%?

MIVACRON (atracurium besilate) in Dextrose 5% is an intravenous neuromuscular blocking agent used during anesthesia. Primarily supplied in prefilled plastic containers, its market presence is driven by anesthesia practices in hospitals and surgical centers globally. The drug's sales are influenced by the demand for surgical procedures and anesthesia services, alongside hospital procurement policies and regulatory approvals.

Market size estimates for neuromuscular blockers in 2022 hovered around $850 million globally, projected to grow at a compound annual growth rate (CAGR) of approximately 4% through 2027.[1] MIVACRON accounts for a significant segment of this market in the hospital setting, especially in regions with higher surgical volumes.

How does the product's formulation influence its market?

Dextrose 5% in plastic containers offers stability, ease of use, and compatibility with existing infusion systems. The plastic container format replaces glass, reducing breakage and allowing for broader usage in different clinical settings.

The formulation aligns with current regulatory trends favoring plastic over glass in parenteral drugs. This preference diminishes manufacturing costs, streamlines storage, and complies with safety standards, thus supporting higher sales volume.

What are the key factors impacting the financial trajectory?

1. Regulatory Environment

Regulatory approvals in key markets—United States (FDA), European Union (EMA), and China (NMPA)—directly affect product availability. Approval delays or withdrawals impact sales. Recent revisions in guidelines emphasizing safety and stability for plastic containers have generally accelerated acceptance.

2. Procurement and Pricing

Hospitals and healthcare providers tend to negotiate price discounts for neuromuscular blockers. MIVACRON’s pricing, typically set per vial or per container basis, fluctuates based on supply chain costs, raw material prices, and competitive dynamics with alternatives like rocuronium and vecuronium.

3. Competitive Landscape

Major players, including Fresenius Kabi, Pfizer, and Teva, dominate the neuromuscular blocking agent market. MIVACRON’s market share depends on pricing strategies, clinical efficacy perceptions, and formulary placements.

4. Surgical and Anesthesia Volumes

Global surgical procedures totaled approximately 340 million in 2022, with elective surgeries leading growth in anesthetic drug demand.[2] Regions with expanding healthcare infrastructure (e.g., Asia-Pacific, Middle East) show increased demand for neuromuscular blockers, favoring MIVACRON's sales trajectory.

5. Supply Chain and Manufacturing

Raw material prices for atracurium or dextrose impact production costs. Supply chain disruptions, such as those caused by the COVID-19 pandemic, increased lead times and costs, affecting short-term revenue.

What is the projected financial trajectory?

Based on current market data, MIVACRON in Dextrose 5% in plastic container is expected to see a CAGR of approximately 3%–5% over the next five years, reaching an estimated market value of $1.1 billion globally by 2027.[1] This growth rate assumes continued surgical volume increases and stability in supply and regulatory approvals.

Key drivers include increasing adoption in emerging markets, product refreshes supporting stability and safety, and expansion in anesthesia standards. Potential downside risks involve regulatory hurdles, shifts towards alternative agents, or ecosystem disruptions impacting hospital procurement.

How do regulatory and market strategies influence future growth?

Companies pursuing strategic registrations in high-growth regions (e.g., China, India, Southeast Asia) can capture additional market share. Emphasis on product differentiation—such as stability in plastic containers—can influence formulary decisions. Price competition pressures may restrict margins but can expand volume.

What are the opportunities and risks for investors?

Opportunities

• Expansion into emerging markets with growing surgical infrastructure.
• Development of new formulations or delivery systems for improved safety.
• Strategic partnerships with hospital systems or government health programs.

Risks

• Competition from generic alternatives and other neuromuscular blockers.
• Regulatory barriers or delays in key jurisdictions.
• Price pressures stemming from government regulations and hospital procurement policies.

Key Takeaways

• The global market for neuromuscular blocking agents is expanding, with MIVACRON in Dextrose 5% in plastic containers positioned as a stable, safe, and convenient option.
• Financial growth hinges on regulatory approval, competitive pricing, and increasing surgical volumes, especially in emerging markets.
• The projected market value could reach approximately $1.1 billion by 2027, with a CAGR of about 4%, contingent on hospital demand, regulatory environment, and competitive dynamics.
• Supply chain stability and innovation in formulation will influence long-term revenue.

FAQs

1. Who are the primary competitors to MIVACRON in this market?
Rocuronium, vecuronium, and rocuronium bromide are the key competitors, with several generic versions also available.

2. How does the plastic container format impact market acceptance?
Plastic containers reduce breakage and are preferred for ease of handling, improving product safety and acceptance in busy clinical environments.

3. What regional factors influence the product’s growth?
High-volume surgical regions such as North America, Europe, and Asia-Pacific drive growth through expanding healthcare infrastructure and regulatory approvals.

4. What are the main cost drivers for MIVACRON?
Raw material prices for atracurium and dextrose, manufacturing costs, supply chain logistics, and regulatory compliance expenses.

5. How does product safety influence its marketability?
Safety features, stability in plastic containers, and regulatory endorsements improve hospital confidence, supporting higher adoption rates.

---

References

[1] MarketsandMarkets. (2022). Neuromuscular Blocking Agents Market. https://www.marketsandmarkets.com/
[2] WHO. (2022). Surgical Procedure Statistics. https://www.who.int/
[3] Drugbank. (2023). Atracurium (MIVACRON). https://go.drugbank.com/